Fresenius Group Overview

Investors

Fresenius Investment Highlights

  • Diversified revenue and earnings base with four strong business segments

  • Leading positions in non-cyclical markets with predictable growth

  • Industry-leading organic growth in all business segments

  • Strong earnings performance and cash flow generation

  • Attractive shareholder returns

  • Prudent financial management

"We were able to sustain our strong momentum also in the second quarter. Strong increases in sales and earnings have put us well on track to reach our full-year targets."
(Stephan Sturm, Chairman of the Management Board)

News

  • Fresenius confirms its guidance after a strong second quarter with double-digit sales and earnings growth

    Stephan Sturm, CEO of Fresenius, said: “We were able to sustain our strong momentum also in the second quarter. Strong increases in sales and earnings have put us well on track to reach our full-year targets..."

    August 01, 2017Fresenius
  • Fresenius appoints Rachel Empey as Chief Financial Officer
    July 21, 2017Fresenius
    Brief News
    Fresenius Helios expands hospital near Berlin

    Fresenius Helios is investing more than €18 million to expand the company’s hospital in the German town of Bad Saarow, about 25 kilometers (15 miles) east of Berlin. The project at HELIOS Hospital Bad Saarow includes construction of a new building that will add bed capacity to meet growing demand, and an expansion of the radiology department. The construction is scheduled for completion in spring 2019.

    July 20, 2017Fresenius Helios
  • Akorn shareholders approve merger agreement with Fresenius Kabi - Closing expected latest by early 2018
    July 20, 2017Fresenius Kabi
    Brief News
    Fresenius wins award for Quirónsalud acquisition

    Fresenius was presented yesterday with the Corporate Finance Award for the company's acquisition of Quirónsalud, Spain’s largest private hospital operator. The award is given annually by the major German business daily Börsen-Zeitung for transactions judged to be outstanding in both strategical and financial terms. Fresenius won in the Large Caps category, which groups major companies. With the Quirónsalud acquisition, the Börsen-Zeitung said, “Fresenius succeeded in making a quantum leap in the hospital business."

    June 23, 2017Fresenius
  • Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Azacitidine, a nucleoside metabolic inhibitor, expands the company's sterile injectable portfolio in oncology.

    June 01, 2017Fresenius Kabi
    Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Vecuronium Bromide, a neuromuscular blocker, expands the company's sterile injectable portfolio in anesthesia.

    May 23, 2017Fresenius Kabi
  • Brief News
    Fresenius Helios opens new hospital facility in northern Germany

    HELIOS Hospital Wesermarsch has gone into operation in a newly built facility in the northern German town of Nordenham. The new hospital building has 120 patient beds, three operating rooms and a hybrid cardiac catheterization lab. Capacity can be increased to 235 beds, if needed. Fresenius Helios invested €36 million in the facility, which took about three years to build, with the County of Wesermarsch contributing an additional €10 million.

    May 22, 2017Fresenius Helios
    Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Clofarabine, a pediatric cancer product, expands the company's sterile injectable portfolio in oncology.

    May 16, 2017Fresenius Kabi
  • Fresenius is off to an excellent start to the year with strong sales and earnings growth
    May 03, 2017Fresenius
    Brief News
    Fresenius' Investment Grade Rating remains unaffected

    Following Fresenius’ announcement to acquire Akorn, Inc. and Merck KGaA’s biosimilars business, the rating agencies Standard & Poor’s (BBB-, stable), Moody’s (Baa3, stable) and Fitch (BBB-, stable) confirm the corporate credit ratings of Fresenius to be unaffected.

    April 26, 2017Fresenius
  • Fresenius Kabi to strengthen and diversify product portfolio by acquiring Akorn and Merck KGaA’s biosimilars business
    April 24, 2017Fresenius Kabi
    Brief News
    Fresenius Kabi USA wins supplier award from Vizient

    Fresenius Kabi USA has won the prestigious 2016 Pharmaceutical Supplier of the Year Award from Vizient Inc., the largest group purchasing organization for U.S. academic medical centers, community hospitals, pediatric facilities, integrated health delivery networks and non-acute health care providers. Fresenius Kabi has won six Vizient awards for service excellence in recent years.

    April 24, 2017Fresenius Kabi
  • Brief News
    Fresenius Vamed wins contract for university hospital building in Austria

    Fresenius Vamed will realize a 350-bed building at University Hospital St. Pölten, in Austria. Working with a partner company, Fresenius Vamed will be the general contractor on the €176 million project. The new building will have some 21,000 square meters (226,000 square feet) of floor space, housing a range of specialist wards. Construction is scheduled to begin in 2019.

    April 21, 2017Fresenius Vamed
    Brief News
    Fresenius Helios modernizing hospital in central Germany

    Fresenius Helios is investing €14 million to modernize its hospital in Wipperfürth, North Rhine-Westphalia. Starting late this month, two wards will be completely renovated and expanded, with three delivery rooms to follow. To minimize disruptions to hospital operations, the individual renovations are being carried out in sequence. When completed in early 2019, they will provide more comfort for patients and reduce the distances that need to be walked inside the hospital.

    April 06, 2017Fresenius Helios
  • Brief News
    Fitch rates Fresenius Finance Ireland Bonds at BBB- and affirms Fresenius at BBB-

    Fitch Ratings has assigned Fresenius Finance Ireland’s €2,600 million notes issued to finance the acquisition of Quirónsalud an instrument rating of BBB-. It also affirmed Fresenius’ corporate credit rating at BBB-. The outlook is stable. The €2,600 million notes were drawn under the newly established Fresenius European Medium Term Note (EMTN) Program and issued by Fresenius Finance Ireland plc., a wholly owned subsidiary of Fresenius SE & Co. KGaA.

    March 23, 2017Fresenius
    Brief News
    Fresenius Helios opens new hospital building in Duisburg

    Fresenius Helios has opened the new building at its hospital in the western German city of Duisburg. The 22,000-square-meter (237,000-square-foot) structure will accommodate up to 350 inpatients. Construction took two years, with Fresenius Helios investing €50 million in the new building. The move from the existing facility into the new building will start later this month.

    March 20, 2017Fresenius Helios
  • Brief News
    Quirónsalud to build Spain’s first proton beam therapy center

    Quirónsalud, a unit of Fresenius Helios, is investing about €40 million to build a proton beam therapy center in Madrid. Scheduled for opening in 2019, it will be the first facility of this type for treating cancer patients in Spain. Currently, every patient who can benefit from proton beam therapy must seek treatment outside the country. In proton beam therapy, the use of a high-energy beam allows tumors to be irradiated with lower total doses of radiation and reduced exposure to surrounding tissue compared with conventional radiation therapy. Quirónsalud will also modernize and expand its radiotherapy clinics in Palmaplanas (Mallorca) and Seville.

    March 10, 2017Fresenius Helios
    Fresenius reports 13th consecutive record year and targets continued strong growth
    February 22, 2017Fresenius
  • Brief News
    Fresenius Kabi launches Dilaudid in prefilled syringe in the U.S.

    Dilaudid (HYDROmorphone HCl injection) is now available in the company’s Simplist™ ready-to-administer prefilled syringe in the United States. This marks the third product launch for the Simplist™ line following ownership by Fresenius Kabi.

    February 17, 2017Fresenius Kabi
    Initial conversion price of equity-neutral convertible bonds fixed

    Fresenius has issued the €500 million equity-neutral convertible bonds due 2024 on January 31, 2017.

    February 02, 2017Fresenius
  • Fresenius Helios closes acquisition of Quirónsalud
    January 31, 2017Fresenius Helios
    Fresenius successfully places equity-neutral convertible bonds
    January 19, 2017Fresenius
  • Fresenius announces issuance of equity-neutral convertible bonds

    Fresenius intends to issue €500 million equity-neutral convertible bonds due 2024.

    January 19, 2017Fresenius
    Fresenius successfully places €2.6 billion in Notes
    January 17, 2017Fresenius
  • Fresenius Helios receives antitrust approval to acquire Quirónsalud
    December 22, 2016Fresenius Helios
    Brief News
    Schuldschein Loans of €1 billion placed

    Fresenius successfully placed €1.0 billion of Schuldschein Loans. Given the substantial investor demand, the volume of the issuance was significantly upsized. The Schuldschein Loans were issued in tranches of five, seven and ten years with fixed and variable interest rates. The proceeds will be used general corporate purposes and the acquisition of Quirónsalud. Funding of the transaction will be on January 31, 2017. More than 230 investors participated. The placement was arranged by Bayerische Landesbank, Deutsche Bank AG, DZ BANK and NORD/LB Norddeutsche Landesbank Girozentrale.

    December 20, 2016Fresenius
  • Brief News
    Fresenius Kabi launches Heparin in prefilled syringe in the U.S

    Heparin Sodium, an anticoagulent, is now available in the company’s Simplist™ ready-to-administer prefilled syringe in the United States. This marks the second new product launch for the Simplist™ line following ownership by Fresenius Kabi. The launch expands Fresenius Kabi’s overall Heparin portfolio.

    December 15, 2016Fresenius Kabi
    Brief News
    Fresenius Kabi and Terumo Cardiovascular Group introduce CATSmart in the U.S.

    CATSmart is Fresenius Kabi’s next-generation continuous autotransfusion system, which helps reduce blood loss during surgery. CATSmart will be distributed in the U.S. by Terumo Cardiovascular Group. Fresenius Kabi USA and Terumo Cardiovascular Group have signed an exclusive, five-year distribution agreement for CATSmart.

    December 14, 2016Fresenius Kabi
  • Brief News
    Fresenius Kabi launches IV drug in the U.S.

    Tigecycline, an antibiotic, expands Fresenius Kabi's anti-infective portfolio.

    December 05, 2016Fresenius Kabi
Disclaimer All News

Library

All Financial Reports

Information & Order Service

Stay informed about the latest news and developments at our Group by subscribing to our Investor News and/or to the Fresenius Brief News. These services are free of charge and may be cancelled at any time.

Please enter your first name.
Please enter your last name.
Please enter your company.
Please enter your department.
Please enter your function.
Please enter your street.
Please enter your postal code and city.
Please enter your e-mail address.

Please send me via email


Do you have other questions or need any more information?
Please send us a message:

To unsubscribe to these services, please send a brief e-mail to ir-fre@fresenius.com or call +49 (0) 6172 608-2470. 

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com


Contact
Visit us

Fresenius SE & Co. KGaA

Fresenius uses cookies on this website to enhance the user experience and provide the best possible service. By continuing to browse the website, you consent to our use of cookies.

Learn more
OK